Interestingly, a retrospective analysis of B2M expression and mutation status in colorectal dMMR cancer patients showed favorable clinical outcomes in patient cohorts despite B2M loss-of-function mutations, counterintuitive to the mechanisms of MHC-I dependance of immune-mediated tumor rejection (99, 100). The gene discussed is B2M; the disease is cancer.